Replies to post #150016 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

I disagree. Missling's management style can be summed up in one word. meticulous.

Once again, in the conference he mentioned trials in "North America". I don't think he will say anything until the Rett trial is approved in the U.S., but if the FDA doesn't get its act together after that is approved I would't be at all surprised if the Alzheimer's 2/3 gets moved to Canada.

I also believe that he may be expecting funding from the U.S. for Alzheimer's. Big Pharma with it's political clout may be causing problems.

My issue is M. has a particular management style which will not work where we want to go

Here is an exceerpt from an article that is worth reading:

Before the U.S. Food and Drug Administration (FDA) approves a prescription drug, it must first go through a series of clinical trials. Data obtained from these trials should ensure the safety and effectiveness of drugs before they make it into the hands of patients.


Big Pharma funds and runs the majority of clinical trials
Each year, the National Institutes of Health’s (NIH) budget provides less money to fund clinical trials. Because of this, Big Pharma pays for and runs the majority of these trials.

It then provides data to the FDA for drug approvals and safety reviews after the drug hits the market. While this practice may help get more drugs approved and allow more treatments to reach patients sooner, it may also lead to unknown risks.

According to critics and consumer watchdogs, Big Pharma’s influence over clinical trials could allow drug companies to focus on the benefits of a drug and downplay the risks for the sake of profit. This biased information could also influence doctors to prescribe a drug without knowing all the risks.

For example, the New England Journal of Medicine — one of the most prestigious medical journals in the world — published 73 studies of new drugs. Of those studies, a pharmaceutical company funded 60, 50 had drug-company employees among the authors and 37 lead researchers had accepted money from a drug company, according to a review conducted by the Washington Post.

This means drug companies greatly influence the majority of medical information provided to the public.

Unreliable clinical trials resulting from the possibility for bias due to Big Pharma influence is an ongoing issue because “clinical trials for pharmaceuticals are conducted and funded by the industry,” Dr. Michael A. Carome, director of the Health Research Group of Public Citizens in Washington, D.C., told Drugwatch.

https://www.drugwatch.com/featured/clinical-trials-and-hidden-data/